相关实验视频

Updated: Sep 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在扩展阶段小细胞肺癌中结合olaparib和胸部辐射治疗的I期剂量升级试验

Andreas Rimner¹, Benjamin H Lok², Daphna Y Gelblum³

¹University of Freiburg, Freiburg, Germany.

Clinical cancer research : an official journal of the American Association for Cancer Research

|August 29, 2025

概括

这一第一阶段试验确定了小细胞肺癌扩散阶段与胸部辐射疗法相结合的最大耐受剂量. 进一步研究的推剂量为每天两次200mg,显示可控的安全性和毒性.

科学领域:

癌症学
辐射瘤学
临床药理学

背景情况:

扩散性小细胞肺癌 (ES-SCLC) 治疗通常包括诱导化疗,随后是巩固性胸部辐射疗法 (TRT).
临床前模型表明PARP抑制剂可以增强肺癌中辐射的辐射效应.
研究人员发起的研究对于探索具有挑战性的癌症新疗法组合至关重要.

研究的目的:

确定ES-SCLC患者同时服用olaparib和低剂量TRT的安全性和最大耐受剂量 (MTD).
在局部复发,无进展生存 (PFS) 和整体生存 (OS) 方面评估该组合的疗效.

主要方法:

进行了一项单臂,开放式,多机构的第一阶段研究.
患者在诱导/ 乙化疗后同时服用口服olaparib和低剂量TRT (30Gy/10分).
首要终点是安全性和MTD.

主要成果:

与TRT联合使用的olaparib的MTD被确定为每天两次200mg.
观察到三种剂量限制性毒性 (3级):肺炎/肺炎,食道炎和腹痛.
12个月的局部复发率为27%,中位数PFS为3. 6个月,中位数OS为17. 7个月.

结论:

这项研究成功地确定了Olaparib每天两次200mg的推II期剂量以及同时使用的低剂量TRT.
这种组合显示出可接受的安全性,没有意外的毒性.
在ES-SCLC患者的II期试验中,该疗法需要进一步研究.

更多相关视频

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...